Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy - Test2 - elhamkhani - TriplyDB

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

http://www.wikidata.org/entity/Q26745686

about

sameAs

The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemia Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Targeting the ATR-CHK1 Axis in Cancer Therapy Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.S-phase checkpoint regulations that preserve replication and chromosome integrity upon dNTP depletion.Chk1 Promotes DNA Damage Response Bypass following Oxidative Stress in a Model of Hydrogen Peroxide-Associated Ulcerative Colitis through JNK Inactivation and Chromatin Binding.Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity.Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.The Impact of DNA Repair Pathways in Cancer Biology and Therapy.Potential Anticancer Mechanisms of a Novel EGFR/DNA-Targeting Combi-Molecule (JDF12) against DU145 Prostate Cancer Cells: An iTRAQ-Based Proteomic Analysis.Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.Molecular Genetic Analysis of Human Endometrial Mesenchymal Stem Cells That Survived Sublethal Heat Shock.Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.C-Terminal Binding Protein is Involved in Promoting to the Carcinogenesis of Human Glioma.A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.A novel role for ATR/Rad3 in G1 phase.Deubiquitinating enzyme USP3 controls CHK1 chromatin association and activation.Germline mutation of CHEK2 in neurofibromatosis 1 and 2: Two case reports.Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia Non‑thermal plasma inhibits tumor growth and proliferation and enhances the sensitivity to radiation in vitro and in vivo The intracellular signalosome of PD-L1 in cancer cells Exploring the links between cancer and placenta development HMGA2 gene silencing reduces epithelial-mesenchymal transition and lymph node metastasis in cervical cancer through inhibiting the ATR/Chk1 signaling pathway Involvement of a coumarin analog AD-013 in the DNA damage response pathways in MCF-7 cells

P2860

Q33913826-DC1C72B2-64FA-41CE-92AD-880F6D1DC83F Q33925006-4C0ED7FC-2B89-4770-B7A7-6131FFA33431 Q37743501-B4AC181A-F584-4890-B6B3-D6161D2B0BE6 Q38608688-B0BEC390-1667-4BF8-93AD-C013E46082C3 Q38660811-C9E75392-86A8-499B-B289-4C10A1B4186D Q38698806-179D136C-1A29-491F-9303-302CEB9600B2 Q38817102-78D963A8-38B2-4194-8A1F-1625B02C6870 Q38838490-F7501984-8371-4B34-B739-67FD524D9B16 Q38989374-388AF386-9341-4428-A1B4-67D3C8062EE1 Q39144822-283BB4C9-82B4-4C56-B442-10A9227148C9 Q41079709-C5DCE799-4204-40EF-8CDC-5F45DD42ADE3 Q41388351-408E97AF-B28F-4E72-9A94-B81A0B03D01F Q41470356-65902CBE-FC0F-422C-9746-27C13BA5B031 Q41545189-77602A3B-2C4E-4668-9EF8-8D960278A486 Q41674995-78456913-705B-4DCE-9A21-D5106F19ABF3 Q42360755-B8C58202-9B0B-4538-8EFB-C7C90C32586F Q42364707-E1056EBE-196A-452D-98BD-0AEA5E7CDD6A Q47156384-C323D95B-EBDC-4B3E-AE0C-6548BC409EDB Q47223079-9776B85C-0FC9-4533-8129-97679AF34380 Q48155911-DC346911-E418-48AB-949B-E77B2B2E018E Q49168184-316BCFCB-4E9C-44ED-8ADF-A0CCEE46AD97 Q50128397-EF8D690D-4D15-4BFE-ABFF-69B3AB0915E7 Q51434672-C9BBD6A4-118F-461F-B846-494B838E4F76 Q52680663-140BAC6F-F247-49FF-BAA8-FEA7196BFD00 Q52714449-44AD4514-511C-45BB-AB29-85306A0649A8 Q53824680-504339C3-B316-4471-9E08-69AA8B05B003 Q54976802-77CF078C-03B0-44B6-ADBA-DD23E7D86524 Q56355417-9E2068BA-60EB-4E6B-8969-0A748E447248 Q57067458-406C9D15-52E3-43C8-8044-A552611AB12C Q57067759-4B2518FF-3D0C-43E6-B914-C83372D38E84 Q57160183-62B3C0E6-9745-4453-8405-57489C01AB11 Q58733935-7C35FAD7-C86C-4E02-9388-DEECF6AFCBB5 Q58796625-6837A440-53FD-4E0B-9EAB-4370EC0B14C6

P2860

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

http://www.wikidata.org/entity/Q26745686

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@ast

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@en

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@nl

type

label

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@ast

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@en

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@nl

prefLabel

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@ast

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@en

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@nl

P1433

Q26745686-832F9388-0100-4214-B712-260F4FAE7983

P1476

Q26745686-15AB6206-B123-49B2-BE55-671A5D977704

P2093

Q26745686-109950D5-96C7-48C4-B300-6AE09E0BE4F1

Q26745686-F97F8107-E75B-47FF-991F-92D85C167125

P2860

Q26745686-0017170D-171F-4586-98F0-5AC0CC8D0482

Q26745686-00446368-BE37-45C5-923D-71856BC5B7B2

Q26745686-00979C08-DDF6-4F06-AF2C-85BE42803D61

Q26745686-00F1E71D-E6A2-4EBA-A70F-4A81D7F9BCD2

Q26745686-018A44DB-1B70-4CC9-90FA-C1F485ED9B5C

Q26745686-0261A950-0821-4C04-971E-E8978BA0937D

Q26745686-027FD21A-127C-4EE4-89C4-599DA1E2BBBF

Q26745686-03DC0DC4-8066-4879-A772-FFFC1494F76D

Q26745686-041344D4-7716-4502-A7D1-B9FA26CC9D90

Q26745686-04A2807E-FFF5-4228-96C9-FA24CCD84E0A

P304

Q26745686-CE00E3C6-2006-4F59-92BB-42EDF0D7A18C

P31

Q26745686-8F889D8D-5CBC-4B58-AE30-16850786F16B

P3181

Q26745686-98BD4A8C-E85F-49D7-B3CF-C6058A38C3BC

P356

Q26745686-4F9DF225-B5D7-4B82-B64D-714EA12B4A19

P407

Q26745686-8C163854-901F-4E7F-99AA-11D2BB72F699

P433

Q26745686-B62F45FC-3F9E-45C8-9980-4CC6D160A943

P478

Q26745686-D8D08A99-ED08-423B-869A-9716E02B15EF

P50

Q26745686-992CFD02-2581-4F6C-ACAE-51A751A5B24D

Q26745686-BBD6C139-82FF-44FE-95C0-01F13E28A076

P577

Q26745686-4988B29F-E836-42BF-ADBF-13D3420B1EEA

P5875

Q26745686-81D94299-AEAF-4FA5-9972-A2D4307970BB

P698

Q26745686-B11DAD60-E3F1-43B8-8162-301927018A5A

P932

Q26745686-F808E5A9-1E85-494C-9668-250907A91CEF

P3181

P356

23723556.2015.1012976

P1433

Molecular & cellular oncology

P1476

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy

@en

P2093

Florine Obrist

http://www.w3.org/2001/XMLSchema#string

Gwenola Manic

http://www.w3.org/2001/XMLSchema#string

P2860

Linkage of ATM to cell cycle regulation by the Chk2 protein kinase

DNA Damage, Aging, and Cancer

CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer

ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex

The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

P304

e1012976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2836409

http://www.w3.org/2001/XMLSchema#string

P356

10.1080/23723556.2015.1012976

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Sistigu

P577

2015-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277975468

http://www.w3.org/2001/XMLSchema#string

P698

27308506

http://www.w3.org/2001/XMLSchema#string

P932

4905354

http://www.w3.org/2001/XMLSchema#string